Feedback
Settings

Settings

Goto Application

1. WO2005093426 - DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH RETINOIC ACID RECEPTOR ALPHA (RARA)

PermaLink
Publication Number WO/2005/093426
Publication Date 06.10.2005
International Application No. PCT/EP2005/002599
International Filing Date 11.03.2005
IPC
A61K 39/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
G01N 33/68 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
G01N 33/74 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
74involving hormones
CPC
G01N 2500/00
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2500Screening for compounds of potential therapeutic value
G01N 33/6875
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
6875Nucleoproteins
Applicants
  • BAYER HEALTHCARE AG [DE]/[DE] (AllExceptUS)
  • GOLZ, Stefan [DE]/[DE] (UsOnly)
  • BRÜGGEMEIER, Ulf [DE]/[DE] (UsOnly)
  • GEERTS, Andreas [DE]/[DE] (UsOnly)
Inventors
  • GOLZ, Stefan
  • BRÜGGEMEIER, Ulf
  • GEERTS, Andreas
Common Representative
  • BAYER HEALTHCARE AG
Priority Data
04007432.026.03.2004EP
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH RETINOIC ACID RECEPTOR ALPHA (RARA)
(FR) DIAGNOSTICS ET THERAPEUTIQUES POUR DES MALADIES ASSOCIEES AU RECEPTEUR D'ACIDE RETINOIQUE ALPHA (RARA)
Abstract
(EN)
The invention provides a human RARA which is associated with the cardiovascular diseases, infections, cancer, endocrinological diseases, metabolic diseases, gastroenterological diseases, hematological diseases, respiratory diseases, inflammation, muscle-skeleton diseases, neurological diseases and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, infections, cancer, endocrinological diseases, metabolic diseases, gastroenterological diseases, hematological diseases, respiratory diseases, inflammation, muscle-skeleton diseases, neurological diseases and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of RARA as well as pharmaceutical compositions comprising such compounds.
(FR)
L'invention concerne un RARA humain associé à des maladies cardio-vasculaires, des infections, des cancers, des maladies endocrinologiques, des maladies métaboliques, des maladies gastro-entérologiques, des maladies hématologiques, des maladies respiratoires, des inflammations, des maladies musculaires/squelettiques, des maladies neurologiques et des maladies urologiques. L'invention concerne également des essais biologiques pour l'identification de composés utiles pour traiter ou pour prévenir des maladies cardio-vasculaires, des infections, des cancers, des maladies endocrinologiques, des maladies métaboliques, des maladies gastro-entérologiques, des maladies hématologiques, des maladies respiratoires, des inflammations, des maladies musculaires/squelettiques, des maladies neurologiques et des maladies urologiques. L'invention concerne également des composés qui se lient et/ou qui activent ou qui inhibent l'activité de RARA, ainsi que des compositions pharmaceutiques comprenant de tels composés.
Latest bibliographic data on file with the International Bureau
# -